研究人员今天发布了最新减肥药物retatrutide的后期临床试验数据，该药物有望成为迄今为止最有效的减肥疗法。
Researchers published late-stage clinical trial data today for the latest obesity drug, retatrutide—expected to be the most powerful formula yet—and the results appear in line with high expectations.
结果显示非常符合预期：接受最高剂量retatrutide治疗的患者在80周后平均体重减轻了25%，在延长至104周的观察期内平均体重减轻了30%。总体而言，超过三分之一的参与者体重减轻了30%或更多。
Patients with obesity on the highest retatrutide dose lost an average of 25 percent of their body weight after 80 weeks, and an average of 30 percent after an extension period to 104 weeks. Overall, more than a third of participants taking retatrutide lost 30 percent or more of their weight.
此外，该药物对患有肥胖相关膝关节炎的参与者有效，可减轻膝盖疼痛（最多达62%）；对于患有肥胖相关阻塞性睡眠呼吸暂停的参与者，该药物还能将每小时睡眠呼吸暂停事件的数量减少（最多达57%）。
The drug also proved effective at reducing knee pain (by up to 62 percent) in a subset of participants with obesity-linked knee osteoarthritis. It reduced the number of sleep apnea events per hour (by up to 57 percent) in a subset of participants with obesity-linked obstructive sleep apnea.
该药物全面改善了心血管代谢指标，包括血压、甘油三酯和低密度脂蛋白胆固醇（坏胆固醇）。
The drug improved cardiometabolic measurements across the board, including blood pressure, triglycerides, and low-density lipoprotein cholesterol (bad cholesterol).
试验开始于2023年，共有来自11个国家131个临床试验地点的2,339名参与者参与。
At the start, more than a third of trial participants had prediabetes and, by the end, the condition had resolved in more than 90 percent of those participants.
参与者被分为四组，分别接受4毫克、9毫克或12毫克的retatrutide治疗，以及安慰剂。
The trial began in 2023 and included 2,339 participants from 131 clinical trial sites in 11 countries. Participants were broken into four nearly equal groups, given either: 4 mg of retatrutide, 9 mg, 12 mg, or a placebo.
所有组的平均起始体重约为113公斤（250磅），平均体质指数（BMI）为40。
Across all groups, the average starting weight was around 113 kg (250 pounds), and the average body mass index (BMI) was 40.
在子组分析中，574名参与者患有膝关节炎，243名参与者患有阻塞性睡眠呼吸暂停。研究结果发表在《新英格兰医学杂志》上。
For the subset analyses, 574 participants had knee osteoarthritis, and 243 had obstructive sleep apnea. The results appeared today in the New England Journal of Medicine.